Immunogenic cell death (ICD)-inducers in non-small-cell lung carcinoma (NSCLC): current knowledge and future perspectiveImmunogenic cell deathImmunotherapyLung cancerNSCLCCALRETICULIN EXPOSURECHEMOTHERAPEUTIC-AGENTSADJUVANT CHEMOTHERAPYCANCERMECHANISMSAPOPTOSISThe prevalence of non-small-cell lung cancer (NSCLC) ...
an anti-PD1 antibody, of whom 22 had sufficient material for RNA sequencing. One patient was later determined to have been treated for squamous cell carcinoma, and was excluded from
Abbreviations: CPI, Checkpoint Inhibitor; HCPCS, Healthcare Common Procedure Coding System; NDC, National Drug Codes; ICD-9/10-CM, International Classification of Disease, Ninth or Tenth Revision, Clinical Modification; CPT, Current Procedureal Terminology; NSCLC, non-small cell lung cancer; PET, ...
Treatment policy of surgery in small cell carcinoma of the lung: retrospective analysis of a series of 874 consecutive patients. Thorax. 1985;40(4):272–7. https://doi.org/10.1136/thx.40.4.272. Article CAS PubMed PubMed Central Google Scholar Lad T, Piantadosi S, Thomas P, Payne D,...
Table S2. Differentially Expressed Genes (DEGs) across Pseudotime and Cell-Type Signatures for Single-Cell Identification of Non-tumor Cell Populations; Cycling Signatures Used to Regress Out Effects due to Cell Proliferation, and Tumor Cell Barcodes Used for Tumor Cell-Specific Analyses from RPM Tra...
Among these patients, there were 1485 patients conformed to our inclusion criteria: only one primary tumor; diagnosis confirmed by histology; histological type of small-cell carcinoma (ICD-O-3); surgery performed. SCLC, also named oat cell carcinoma, with histological codes included as follows: ...
Advanced non-small-cell lung carcinoma (NSCLC) treatment has been based on cytotoxic chemotherapy for decades, with a doublet of platinum in combination with several others agents [4]. The first therapeutic evolution was related to the discovery of targetable oncogenic mutation using mainly a small...
Data regarding the association between photodynamic therapy (PDT) and mortality in lung cancer patients are limited. We analyzed the association between PDT and mortality in patients with stage III or IV non-small cell lung cancer (NSCLC) using data from